Fig. 4

The comparison of ROC curves for survival of PD-L1, ESCC-PS and ESCC-PS + PD-L1 in validation cohort. A The comparison of ROC curves for evaluating 6-month PFS (AUROC: 0.610, 0.924 and 0.904). B The comparison of ROC curves for evaluating 12-month PFS (AUROC: 0.679, 0.857 and 0.868). C The comparison of ROC curves for evaluating 12-month OS (AUROC: 0.643, 0.886 and 0.901). D. The comparison of ROC curves for evaluating 18-month OS (AUROC: 0.626, 0.838 and 0.883). ROC receiver operating characteristic, AUROC area under ROC curve, PFS progression-free survival, OS overall survival, ESCC-PS esophageal squamous cell cancer-pathomics signature